Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.46 |
| ▸ | MAOB | P27338 | 11/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128091 | 0.82 | NPC1 (0.81) | NPC1RAB9AMAPTHRH3MAOB | |
| SCHEMBL8764585 | 0.82 | NPC1 (0.62) | NPC1RAB9AMAPTHRH3MAOB | |
| SCHEMBL779443 | 0.81 | NPC1 (0.58) | NPC1RAB9AMAPTHRH3MAOB | |
| SCHEMBL3436081 | 0.80 | NPC1 (0.60) | NPC1RAB9AMAPTHRH3MAOB | |
| SCHEMBL27856300 | 0.78 | NPC1 (0.63) | NPC1RAB9AMAPTHRH3MAOB | |
| SCHEMBL825336 | 0.78 | NPC1 (0.58) | NPC1RAB9AMAPTHRH3MAOB | |
| SCHEMBL805161 | 0.78 | NQO1 (0.61) | NPC1RAB9AMAPTHRH3MAOB | |
| SCHEMBL24785659 | 0.78 | NPC1 (0.53) | NPC1RAB9AMAPTHRH3MAOB | |
| SCHEMBL11964382 | 0.77 | NPC1 (0.56) | NPC1RAB9AMAPTHRH3MAOB | |
| SCHEMBL14706810 | 0.77 | NPC1 (0.56) | NPC1RAB9AMAPTHRH3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8105668-B2 | Crystalline form of 2-(4,6-bis-biphenyl-4-yl-1,3,5-triazin-2-yl)-5-(2-ethyl-(n)-hexyloxy)phenol | BASF SE (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20110027509-A1 | CRYSTALLINE FORM OF 2-(4,6-BIS-BIPHENYL-4-YL-1,3,5-TRIAZIN-2-YL)-5-(2-ETHYL-(N)-HEXYLOXY)PHENOL | BASF SE (US) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110027509-A1 | CRYSTALLINE FORM OF 2-(4,6-BIS-BIPHENYL-4-YL-1,3,5-TRIAZIN-2-YL)-5-(2-ETHYL-(N)-HEXYLOXY)PHENOL | CRYZ, H1-4, H1-2 | NPC1 3058/4885RAB9A 3490/4885MAPT 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.